SECsense Logo

Aspire Biopharma Holdings, Inc. 8-K Report: Key Corporate Updates & Stock Insights

$PWUP
Form 8-K
Filed on: 2025-02-20
Source
Aspire Biopharma Holdings, Inc. 8-K Report: Key Corporate Updates & Stock Insights

Based on the provided XML section of the financial report, here are the key pieces of information and insights extracted:

  1. Company Identification:
  • Entity Name: Aspire Biopharma Holdings, Inc.
  • CIK Number: 0001847345
  • SEC File Number: 001-41293
  • Tax ID (EIN): 33-3467744
  1. Address:
  • Former Address: 194 Candelaro Drive #233, Humacao, PR 00791
  • Current Address: 188 Grand Street Unit #195, New York, NY 10013
  1. Filing Date:
  • Report Date: February 13, 2025
  • Type of Filing: Form 8-K
  1. Stock Information:
  • Common Stock:
    • Par Value: $0.0001 per share
    • Trading Symbol: ASBP (listed on NASDAQ)
  • Warrants:
    • Description: Each warrant is exercisable for one share of common stock.
    • Trading Symbol: ASBPW (listed on NASDAQ)
  1. Contextual Information:
  • The filing has a specific context defined for the period starting and ending on February 13, 2025. This suggests that the report may include recent developments or events occurring on this specific date.
  1. Units of Measurement:
  • Currency: United States Dollar (USD)
  • Shares: The report uses shares as a unit of measurement for stock-related activities.

Insights:

  • The company is involved in significant corporate actions, as indicated by the 8-K filing, which is typically used to report major events that shareholders should know about.
  • The presence of warrants indicates potential future dilution of common stock, which may impact existing shareholders.
  • The company has undergone an address change, which could imply operational changes or restructuring.
  • The specific par value of the shares (very low at $0.0001) is typical for companies that might be in early stages or looking to attract investors through lower entry costs.

This report provides a snapshot of Aspire Biopharma Holdings, Inc.'s current status regarding corporate filings and stock information as of the specified date. Further analysis would involve examining additional details in the full report for insights on financial performance, governance, and strategic direction.